- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about edit
Recent news which mentions edit
The 3 Best CRISPR Stocks to Buy Now Before They Skyrocket
March 25, 2023
From InvestorPlace
Thinking of Buying Biotech Stocks? Do These 3 Things First
March 22, 2023
From Motley Fool
These 2 Biotech Stocks Could Soar in the Next Bull Market
February 17, 2023
From Motley Fool
From Motley Fool
3 No-Brainer Stocks to Buy Right Now for Less Than $25
February 04, 2023
From Motley Fool
Why Editas Medicine's Shares Jumped This Week
February 03, 2023
From Motley Fool
Is Editas Medicine Stock a Buy Now?
February 03, 2023
From Motley Fool
3 CRISPR Stocks to Buy Now Or You’ll Be Kicking Yourself Later
February 02, 2023
From InvestorPlace
Analyst Initiates Coverage On This Peer Lagging Gene-Editing Stock
February 01, 2023
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 1, 2023
February 01, 2023
From Benzinga
7 CRISPR Stocks With the Best Long-Term Potential
January 30, 2023
From InvestorPlace
Shoreline Biosciences Acquires Editas' iNK Cell Franchise, Related Gene Editing Technologies
January 19, 2023
Tickers
EDIT
From Benzinga
3 CRISPR Stocks That Will Make You Filthy Rich in 10 Years
January 18, 2023
From InvestorPlace
Precigen's Overnight Cell Manufacturing Technology Could Offer Advanced AML Patients The Option Of Promising CAR-T Therapy
December 08, 2022
From Benzinga
2 Beaten-Down Stocks to Watch Closely Next Year
December 06, 2022
From Motley Fool
Editas Medicine Touts Positive Safety, Efficacy Data From Two Sickle Cell Disease Patients
December 06, 2022
Tickers
EDIT
From Benzinga
Why Shares of Editas Medicine Dropped 15.5% in November
December 05, 2022
Tickers
EDIT
From Motley Fool
Where Will Editas Medicine Be in 1 Year?
November 20, 2022
From Motley Fool
Gene Editing Stock's Prospects Cut In Half By Analyst, Citing Limited Value In Retina Treatment
November 18, 2022
Tickers
EDIT
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 18, 2022
November 18, 2022
From Benzinga
Palo Alto To Surge Around 38%? Plus This Analyst Predicts $65 For Helmerich & Payne
November 18, 2022
From Benzinga
Intuit To $490? Here Are 5 Other Price Target Changes For Friday
November 18, 2022
From Benzinga
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.